Realtime continuous glucose monitoring (RT-CGM), which provides a glucose reading and trend every five minutes for up to seven days, is a valuable diabetes management tool for people with type 1 diabetes who, in their quest for tight glycemic control, are particularly vulnerable to severe and potentially life-threatening hypoglycemia. The value of RT-CGM for people with type 2 diabetes is less well recognized, particularly for those who are non-insulin treated. This paper reviews the still nascent literature documenting the efficacy of RT-CGM in people with type 2 diabetes and then addresses the advantages and disadvantages of its use from the perspectives of the healthcare provider and the patient.
diabetes not using prandial insulin. 2 This is the largest study in patients with type 2 diabetes to date. The RT-CGM device was used for four three-week cycles (two weeks on/one week off). Subjects randomized to RT-CGM were asked to perform SMBG to calibrate the RT-CGM device as directed by the manufacturer in order to confirm the RT-CGM values before each meal, at bedtime, and for all episodes of hypoglycemia (<70 mg/dl) or hyperglycemia (>180 mg/dl). Patients randomized to SMBG were asked to perform SMBG before each meal and at bedtime.
All patients were managed by their usual provider and were instructed to contact their primary care provider for all treatment decisions; there was no therapeutic intervention by the study team.
The intention-to-treat analysis of the data showed that RT-CGM significantly reduced HbA 1c compared with SMBG alone during the time of its use (-1.1 versus -0.5 %) and the HbA 1c reduction was sustained for the following 40 weeks (-0.8 versus -0.2 %). In a per protocol analysis of the data comparing those who used the RT-CGM device for <48 days versus those who used it for ≥48 days (the maximum possible use was 56 days), the HbA 1c differences were even greater at 12 weeks (-1.3 versus -0.6 %) and at 52 weeks (-1.0 versus -0.2 %). There was a significant reduction in weight during the first 12 weeks as well.
Although not statistically significant, the trend toward weight loss in the RT-CGM group persisted for the remaining 40 weeks.
A recent health economics analysis based on the findings from the study by Fonda (-0.6 ± 0.1 %; p<0.0001) in 30 patients with type 2 diabetes who were taking insulin and/or oral agents. 5 However, there was no significant improvement in the seven patients using oral only agents.
Studies Showing Efficacy of Continuous Glucose Monitoring in People with Type 2 Diabetes
Fritschi et al. conducted a descriptive study that examined the experience of 35 women with type 2 diabetes wearing a masked CGM device for three days. 6 Eighty-six percent of patients were surprised by their blood glucose values; specifically, they did not realize the values could go as high as 300 mg/dl. Ninety-four percent stated that the information they learned from the CGM device would positively change the way they took care of their diabetes, including a change of diet (60 %) and an increase in physical activity (34 %).
Allen et al. assessed the effectiveness of two interventions, CGM and problem-solving skills compared with CGM counseling and general diabetes education, in a two-week pilot study involving 29 women with type 2 diabetes, a mean age of 53 years, a mean duration of diabetes of 6.7 years, and suboptimal glycemic control. 7 The study showed the CGM and problem-solving intervention increased problem-solving skills with a subsequent improvement in diet, minutes of moderate physical activity, weight, and HbA 1c .
Advantages of Realtime Continuous Glucose Monitoring-The Provider's Perspective

Glycemic Variability
Glycemic variability is the degree of fluctuation around mean blood glucose levels. It has been hypothesized that a reduction in glycemic variability-independent of HbA 1c reduction-may decrease the number and severity of diabetes complications. [8] [9] [10] One of the main advantages of RT-CGM over SMBG, from the provider's perspective, is that it is a clinical tool that can aid in the identification (and treatment) of glycemic variability, which is becoming an important metric in providing a more complete view of glycemic control. Unfortunately, the amount of glucose data necessary to calculate accurate measures of glycemic variability is large and not likely to be provided consistently by all patients with type 2 diabetes using SMBG. RT-GM provides a relatively simple tool for this purpose, and most software supporting RT-CGM devices automatically calculates multiple measures of glycemic variability after data upload.
Glycemic variability may contribute to the development of diabetes complications via the production of oxidative stress. Blood Glucose Monitoring
(glucose concentrations >180 mg/dl) 38 ± 4 % of the day. 16 Moreover, the researchers found that even diabetes patients with an HbA 1c <7 % experienced hyperglycemia for as much as 24 ± 5 % of the time throughout the day.
Using masked CGM to examine the correlations between HbA 1c levels and metabolic control (average glucose) with various measures of glycemic variability in 68 patients (33 of whom had type 2 diabetes), Sartore et al. found no significant correlation between average glucose or HbA 1c and the variability measures (e.g., SD). The authors concluded that HbA 1c levels reflect averages and sustained hyperglycemic fluctuations, but are not sensitive to short and rapid glucose swings during a 24-hour period. They suggested that SD should be a fundamental parameter for optimal diabetes management. 17 
Duration of Glucose Excursions
Additionally, CGM and RT-CGM give information regarding the duration of glucose excursions contributing to glycemic variability. The identification of glucose trends and periods of hypoglycemia and hyperglycemia may induce more timely and more accurate intensification of therapy when indicated.
Disadvantages of Realtime Continuous Glucose Monitoring-The Provider's Perspective
The effective use of RT-CGM requires that providers take time to review and understand the glucose graphs and trends in order to make the most appropriate treatment decisions. In the absence of a diabetes educator, providers who wish their patients to use RT-CGM may also need to instruct them in its use. Finally, a substantial amount of documentation regarding the need to use CGM or RT-CGM, especially in non-insulin-treated patients, will require time to complete, which may not be compensated by third-party payers.
Advantages of Realtime Continuous Glucose Monitoring-The Patient's Perspective
Before discussing advantages of RT-CGM from the patient's perspective, it is important to consider why SMBG is not as effective as it might be in patients with type 2 diabetes-especially those who are non-insulin-treated-and why its use is controversial.
Use of Self-monitoring of Blood Glucose
The findings from several reviews and meta-analyses suggest that SMBG 
